Alla studier
Aktiv men inte rekryterandeFAS1INTERVENTIONELL

A Study to Evaluate the Safety, Tolerability, and Effects on Blood and Urine Markers of Single Ascending Dose of GSK4771261 in Healthy Participants and Participants With Autosomal Dominant Polycystic Kidney Disease

This study is testing a new medication called GSK4771261. It's a 'Phase 1' study, which means it's one of the first steps in checking if a new drug is safe and how it works in people. No one, not even the doctors or participants, will know who is getting the new drug or a dummy pill. The study has two main parts. Part A involves healthy volunteers to see if the new drug is safe and how their bodies react to it. Part B is similar but focuses on people who have a type of kidney disease called autosomal dominant polycystic kidney disease (ADPKD). Researchers want to see if the drug affects their blood and urine markers.

Överblick

Status
Aktiv men inte rekryterande
Fas
FAS1
Sponsor
GlaxoSmithKline
Inskrivningsmål
86
Starta
11 dec 2024
Beräknad slutförande
23 Jul 2027

Vad handlar denna studie om?

This study is trying to understand more about a new medication called GSK4771261. Think of it as a very early stage of testing for a new drug. The main goals are to check if it's safe for people to take, how much of it stays in the body, and what effects it has on various measurements in your blood and urine.

The study is split into two groups. The first group, called Part A, involves healthy volunteers. This helps researchers understand the basic safety of the drug and how it works in bodies that aren't already affected by illness. The second group, Part B, will include people who have a specific inherited kidney condition called autosomal dominant polycystic kidney disease (ADPKD). By studying people with ADPKD, the researchers hope to learn if this new drug could potentially help manage or treat this condition.

It's important to know that this is a 'blinded' study. This means neither you, nor the study doctors, will know whether you are receiving the new drug or a 'placebo' – which looks identical but contains no active medicine. This helps make sure the study results are fair and unbiased. The findings from this study will help decide if this new drug should be tested further in larger studies.

Viktiga punkter

  • This study is testing a brand-new drug, GSK4771261, for safety and its effects.
  • It involves both healthy people (Part A) and those with ADPKD (Part B).
  • No one will know if they are receiving the drug or a 'dummy' pill.
  • The study checks blood and urine changes as well as general safety.
  • It's an early-stage 'Phase 1' study for potential future ADPKD treatment.

Vem kan vara berättigad?

To join this study, you generally need to be a man or a woman aged between 25 and 65 years old. You also need to weigh at least 45 kilograms (about 7 stone 1 pound) and have a healthy body mass index (BMI) between 19.5 and 32. All participants must be able to understand the study and agree to take part by signing a consent form.

For Part A, you must be a healthy adult with no major ongoing health problems, as assessed by the study doctor. For women, you must have gone through menopause, had a hysterectomy or fallopian tubes tied, or have other reasons why you can't have children.

If you have Autosomal Dominant Polycystic Kidney Disease (ADPKD) and are interested in Part B, you must have a confirmed diagnosis of this condition. While you might have some health issues related to ADPKD, you should otherwise be in good general health. Your kidney function, measured by something called eGFR, needs to be reasonably good (at least 45 mL/min/1.73m²), and your doctor shouldn't expect it to get much worse quickly. You'll also need to have certain types of ADPKD based on imaging scans and a confirmed genetic fault related to the condition.

Kan denna studie passa dig?

Svara på dessa snabba frågor för att se om du kan vara berättigad. Detta är endast en vägledning — forskarteamet fattar det slutgiltiga beslutet.

  1. Är du mellan 25 och 65 år gammal?
  2. Do you weigh at least 45 kilograms (about 7 stone 1 pound)?
  3. Is your Body Mass Index (BMI) between 19.5 and 32?
  4. For women, are you unable to have children (e.g., post-menopause, sterilised)?
  5. For Part B, do you have a confirmed diagnosis of ADPKD?
Svara på varje fråga för att se ditt resultat.

Vad innebär deltagande?

If you decide to take part in this study, you will be given either the new drug, GSK4771261, or a 'dummy' pill (placebo) that looks exactly the same. No one involved will know which you are receiving. You will need to come for several visits to the study clinic where doctors will check your health, take blood and urine samples, and monitor how your body is reacting to the treatment. They'll also perform other tests like physical exams and heart checks. The study length isn't specified, but Phase 1 studies often involve regular visits over weeks or months, followed by a period where researchers continue to check on your health. You will be told the exact schedule of visits and tests during the consent process.

Potentiella risker och fördelar

Participating in a clinical trial like this could offer potential benefits, such as contributing to scientific understanding about ADPKD and potentially gaining early access to a new treatment, though there's no guarantee the treatment will directly benefit you. However, there are also potential risks involved, mainly from the new drug itself, which might cause side effects that we don't fully know about yet. You might also experience discomfort from blood tests and other procedures. It's really important to remember that you can stop participating in the study at any time, for any reason, without it affecting your usual medical care.

Locations (23)

  • GSK Undersökningsplats
    Verifierat postnummer
    Rochester, USA
  • GSK Undersökningsplats
    Verifierat postnummer
    Bryssel, Belgien
  • GSK Undersökningsplats
    Verifierat postnummer
    Gent, Belgien
  • GSK Undersökningsplats
    Verifierat postnummer
    Leuven, Belgien
  • GSK Undersökningsplats
    Verifierat postnummer
    London, Kanada
  • GSK Undersökningsplats
    Verifierat postnummer
    Toronto, Kanada
  • GSK Undersökningsplats
    Verifierat postnummer
    Montreal, Kanada
  • GSK Undersökningsplats
    Verifierat postnummer
    Brest, Frankrike
  • GSK Undersökningsplats
    Verifierat postnummer
    Paris, Frankrike
  • GSK Undersökningsplats
    Verifierat postnummer
    Köln, Tyskland
  • GSK Undersökningsplats
    Verifierat postnummer
    Lübeck, Tyskland
  • GSK Undersökningsplats
    Verifierat postnummer
    Groningen, Nederländerna

Vanliga frågor

What is Autosomal Dominant Polycystic Kidney Disease (ADPKD)?

ADPKD is an inherited kidney condition where cysts (fluid-filled sacs) grow in the kidneys, which can cause them to become very large and affect how well they work.

Vad är en 'Fas 1'-studie?

Phase 1 is the earliest stage of human testing for a new drug. It mainly checks if the drug is safe, what dose is best, and how the body handles it.

What does 'blinded' mean in this study?

Being 'blinded' means neither you nor the study doctors will know if you are receiving the new drug or a dummy pill (placebo). This helps make the study fair.

Will I know if the new drug is working for me?

Because this is an early-stage study and it's 'blinded,' you won't know if you're getting the active drug or a placebo during the study. The main focus is on safety and how your body reacts.

Kan jag sluta delta i studien om jag ändrar mig?

Yes, absolutely. You are free to withdraw from the study at any time, for any reason, without it affecting your normal medical care.

Hur du får reda på mer

Prata alltid med din läkare eller specialist innan du bestämmer dig för att delta i en studie.

Diskussion

Gemenskapsdiskussion

Drivs av vårt forum på community.patient.info. Var vänlig och respektfull — detta är inte medicinsk rådgivning.